Eversense E3 offers your patients survivability, reliability and flexibility.
Don’t let interruptions caused by 7-14 day CGMs be the reason your patients have gaps in usage. The Eversense E3 system gives you the data you need, and your patients the peace of mind they deserve.
#1 CGM in Survivability & Longevity1-3
95% of Eversense E3 sensors survive the full 6 months - which means fewer interruptions in CGM therapy.
Sensor Survivability1-3
Expected Sensor Life1-3
Eversense E3 is designed to overcome the limitations of short-term CGM systems.
Most accurate in low glucose ranges1-3
Eversense E3 has unparalleled accuracy when it matters most.1-3
Delivers accurate readings with only 1 day one across 6 months1-3
Across 180 days with 10 day short term sensors, there are 18 sensor sessions with associated variability for each.4
Most dependable detection alerts1
On-body alerts discreetly notify of predictive high or low.
Eversense E3 is Designed for Those Seeking CGM Longevity, Reliability, and Flexibility
An optimal choice for adults with diabetes on Insulin.
Behind our exceptional accuracy is patented fluorescent technology.
Eversense E3 sensors use fluorescent light technology to measure glucose in interstitial fluid. The intensity of the light signal rises and falls in proportion to the body’s glucose levels. There is no interference with glucose measurements from Vitamin C or acetaminophen.
Ready to Become a Provider?
Learn more about what steps you can take to prescribe Eversense or how to become an Eversense Inserter.
1. Senseonics. (2023) Eversense E3 Continuous Glucose Monitoring System User Guide. LBL-6002-01-001_Rev C
2. Dexcom. (2023) G7 User Guide. AW00078-10 Rev 002 MT-00078-10
3. Abbott. (2022) FreeStyle Libre 3 Flash Glucose Monitoring System User Manual. ART43911-001 Rev. B 06/22
4. Garg SK, Kipnes M, Castorino K, Bailey TS, Akturk HK, Welsh JB, Christiansen MP, Balo AK, Brown SA, Reid JL, Beck SE. Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes. Diabetes Technol Ther. 2022 Jun;24(6):373-380.
Disclaimer
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For safety information click here.
Eversense, Eversense E3 Continuous Glucose Monitoring and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, and the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
PP-SENS-E3-GBL-0067